Literature DB >> 8450995

Cyclosporine increases muscular force generation in Duchenne muscular dystrophy.

K R Sharma1, M A Mynhier, R G Miller.   

Abstract

We investigated the effect of cyclosporine (CsA) on force generation in 15 boys with Duchenne muscular dystrophy (DMD) by obtaining monthly measures of tetanic force and maximum voluntary contraction (MVC) of both anterior tibial muscles. During 4 months of a natural history phase, both tetanic force and MVC declined significantly. During 8 weeks of CsA treatment (5 mg/kg/day), significantly increased tetanic force (25.8 +/- 6.6%) and MVC (13.6 +/- 4.0%) occurred within 2 weeks. The maximum mean increase during treatment was 35.2 +/- 5.9% (tetanic force) and 19.0 +/- 4.6% (MVC). Side effects from CsA, gastrointestinal and flu-like symptoms, were transient and self-limiting. Thus, as previously reported with prednisone, CsA increases muscular force generation in the anterior tibial muscles of DMD patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8450995     DOI: 10.1212/wnl.43.3_part_1.527

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  16 in total

1.  RSK2 mediates muscle cell differentiation through regulation of NFAT3.

Authors:  Yong-Yeon Cho; Ke Yao; Ann M Bode; H Robert Bergen; Benjamin J Madden; Sang-Muk Oh; Svetlana Ermakova; Bong Seok Kang; Hong Seok Choi; Jung-Hyun Shim; Zigang Dong
Journal:  J Biol Chem       Date:  2007-01-09       Impact factor: 5.157

2.  A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice.

Authors:  Annamaria De Luca; Beatrice Nico; Antonella Liantonio; Maria Paola Didonna; Bodvael Fraysse; Sabata Pierno; Rosa Burdi; Domenica Mangieri; Jean-François Rolland; Claudia Camerino; Alberta Zallone; Paolo Confalonieri; Francesca Andreetta; Elisa Arnoldi; Isabelle Courdier-Fruh; Josef P Magyar; Antonio Frigeri; Michela Pisoni; Maria Svelto; Diana Conte Camerino
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

Review 3.  Pharmacologic and genetic therapy for childhood muscular dystrophies.

Authors:  D M Escolar; C G Scacheri
Journal:  Curr Neurol Neurosci Rep       Date:  2001-03       Impact factor: 5.081

Review 4.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

5.  Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy.

Authors:  Jin-Hong Shin; Xiufang Pan; Chady H Hakim; Hsiao T Yang; Yongping Yue; Keqing Zhang; Ronald L Terjung; Dongsheng Duan
Journal:  Mol Ther       Date:  2013-01-15       Impact factor: 11.454

6.  Activation and cellular localization of the cyclosporine A-sensitive transcription factor NF-AT in skeletal muscle cells.

Authors:  K L Abbott; B B Friday; D Thaloor; T J Murphy; G K Pavlath
Journal:  Mol Biol Cell       Date:  1998-10       Impact factor: 4.138

Review 7.  Therapeutics in duchenne muscular dystrophy.

Authors:  Jonathan B Strober
Journal:  NeuroRx       Date:  2006-04

Review 8.  Immune-mediated pathology in Duchenne muscular dystrophy.

Authors:  Amy S Rosenberg; Montserrat Puig; Kanneboyina Nagaraju; Eric P Hoffman; S Armando Villalta; V Ashutosh Rao; Lalage M Wakefield; Janet Woodcock
Journal:  Sci Transl Med       Date:  2015-08-05       Impact factor: 17.956

9.  Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy.

Authors:  J Reutenauer; O M Dorchies; O Patthey-Vuadens; G Vuagniaux; U T Ruegg
Journal:  Br J Pharmacol       Date:  2008-07-21       Impact factor: 8.739

10.  Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine.

Authors:  P Bernasconi; E Torchiana; P Confalonieri; R Brugnoni; R Barresi; M Mora; F Cornelio; L Morandi; R Mantegazza
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.